SynAct Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-111.63	-110.83	-82.4	-215.81	-99.21	-69.3
Depreciation & Amortization	0.63	0.63	0.62	75.34	1.02	0.09
Loss (Gain) From Sale of Assets	-	-	-0.05	-0.04	-0.01	-
Stock-Based Compensation	1.89	1.89	10.07	7.88	-	-
Other Operating Activities	2.29	3.49	0.85	2.09	1	-2.88
Change in Accounts Receivable	13.3	13.3	-19.63	19.87	-19.31	-1.21
Change in Accounts Payable	-7.04	-7.04	7.33	5.11	0.18	1.44
Change in Other Net Operating Assets	-0.9	1.22	-5.97	5.39	-1.22	6.87
Operating Cash Flow	-101.46	-97.33	-89.2	-100.18	-117.56	-65
Investment in Securities	-	-	-	0.37	0.03	-0.01
Investing Cash Flow	-	-	-	0.37	0.03	-0.01
Long-Term Debt Repaid	-	-0.58	-0.6	-0.73	-0.98	-0.08
Net Debt Issued (Repaid)	-0.58	-0.58	-0.6	-0.73	-0.98	-0.08
Issuance of Common Stock	92.21	92.21	94.14	59.46	228.95	80
Other Financing Activities	29.43	-1.18	-6.14	-4.75	-27.25	-5.6
Financing Cash Flow	116.06	90.46	87.41	53.98	200.71	74.32
Foreign Exchange Rate Adjustments	0.01	-0.93	0.61	-0.03	1.06	0.13
Miscellaneous Cash Flow Adjustments	0	0	-0	-	0	-0
Net Cash Flow	14.62	-7.8	-1.19	-45.85	84.25	9.45
Cash Interest Paid	0.87	2.38	0.98	0.12	0.12	0.11
Cash Income Tax Paid	-	-8.16	-8.43	-8.47	-7.86	-4.63
Levered Free Cash Flow	-66.22	-62.83	-62.5	18.74	-86.61	-43.28
Unlevered Free Cash Flow	-66.22	-62.27	-61.99	19.24	-86.43	-43.21
Change in Working Capital	5.37	7.49	-18.28	30.37	-20.35	7.1